Vertex’s CEO was an AI skeptic. But not anymore.

Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
MyChesCo on MSN

Vertex Reports Strong Q3 Results and Unveils $150 Million Stock Buyback Plan

Vertex, Inc. (NASDAQ: VERX) posted double-digit revenue growth in the third quarter of 2025 and announced its first-ever ...